Bengaluru: Pharmacy Company Mylan NV is going to launch its generic version of Gilead Sciences Inc’s Covid- 19 medicine Remdesivir this month. The company on Monday said that 100 mg vial medicine price is Rs. 4, 800, as infection surge in the world’s third worst hit country.
According to the company’s statement, the (DCGI) approved Mylan’s Remdesivir version, to be called Desrem, for the treatment of suspected or laboratory confirmed severe incidences of COVID-19 in adults and children, the company said in a statement. Gilead has priced Remdesivir at $2,340 per patient for wealthier nations. It has agreed to send nearly all of its supply of the drug to the United States over the next three months, stirring concerns about availability elsewhere.
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial. On Friday, it got conditional approval from the European Commission for use in severe COVID-19 patients. Mylan said it was working toward expanding emergency use access for patients in the 127 low- and middle-income countries where it is licensed by Gilead Sciences to do so.
Gilead has signed licensing agreements with Dr. Reddy’s Laboratories Ltd, Jubilant Life Sciences Ltd, Syngene International Ltd and Zydus Cadila, listed as Cadila Healthcare Ltd, to make and sell Remdesivir.